Twist Bioscience Co. (NASDAQ:TWST) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lifted its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 74.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 331,373 shares of the company’s stock after purchasing an additional 141,557 shares during the period. Ensign Peak Advisors Inc owned approximately 0.57% of Twist Bioscience worth $16,330,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TWST. American International Group Inc. grew its stake in shares of Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after acquiring an additional 213 shares in the last quarter. Caprock Group LLC grew its stake in Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares in the last quarter. Arizona State Retirement System grew its stake in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after purchasing an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after purchasing an additional 312 shares during the period. Finally, CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. TD Cowen raised their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Finally, The Goldman Sachs Group upped their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.22.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $45.29 on Tuesday. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -13.48 and a beta of 1.76. The stock’s 50-day moving average is $47.05 and its two-hundred day moving average is $43.14.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company’s quarterly revenue was up 27.7% on a year-over-year basis. During the same period last year, the firm earned ($1.01) EPS. As a group, research analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at approximately $3,547,261.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Dennis Cho sold 709 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the transaction, the insider now owns 78,996 shares of the company’s stock, valued at $3,154,310.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 1,137 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the sale, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The disclosure for this sale can be found here. Insiders sold a total of 15,125 shares of company stock worth $664,784 in the last 90 days. 3.92% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.